Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
At a glance
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Sponsor
- Mirati Therapeutics Inc.
- Enrolment target
- 626
- Started
- 2 December 2020
- Main results due (estimated)
- 31 October 2028
- Study ends (estimated)
- 31 October 2029
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- None
- Sites
- 770 · 22 in India
- First posted
- 3 November 2020
- Registry updated
- 30 October 2026
MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab and Pembrolizumab alone
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS * Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS\>=50% * Phase 3: Presence of measurable disease per RECIST1.1 * Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following: 1. No evidence of brain metastases 2. Untreated brain metastases not needing immediate local therapy 3. Previously treated brain metastases not needing immediate local therapy Exclusion Criteria: * Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510). * Phase 2: Active brain metastases * Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following: 1. Any untreated brain lesions \> 2.0 cm in size 2. Any brainstem lesions 3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \> 10 mg of prednisone (or equivalent) prior to randomization. 4. Have poorly controlled (\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy * Phase 3: Radiation to the lung \> 30 Gy within 6 months prior to the first dose of study treatment
What this study is about
In the sponsor’s own words, from the registry.
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Read the detailed description
The Phase 2 portion of this study will evaluate the efficacy and safety of MRTX849 as monotherapy and in combination with pembrolizumab. There will be 3 cohorts of patients, all of whom have KRAS G12C mutation, have advanced or metastatic NSCLC, and are candidates for first-line treatment. 2 cohorts have PD-L1 TPS score \<1% and are randomized to MRTX849 monotherapy or MRTX849 in combination with pembrolizumab. The 3rd cohort has PD-L1 TPS score of 1% or higher and is treated with MRTX849 and pembrolizumab
The Phase 3 portion of the study will randomize patients with squamous or nonsquamous NSCLC with KRAS G12C mutation and TPS \>=50% in the first-line setting to adagrasib plus pembrolizumab or pembrolizumab. Primary efficacy objective is to compare efficacy between experimental and comparator arms. Secondary and exploratory objectives include evaluation of secondary efficacy endpoints, safety and tolerability, adagrasib PK, PROs, and correlative genomic biomarkers for the combination regimen in the study population.
MRTX849 is an orally available small molecule inhibitor of KRAS G12C, and Pembrolizumab (KEYTRUDA®) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Keywords: KRAS G12C · Non-small cell lung cancer · NSCLC · Metastatic Non-Small Cell Lung Cancer · Adagrasib · Krazati · TPS
What participants receive
- Experimental
Phase 2 Cohort 1a: PD-L1 TPS <1%
Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab
Drug: Adagrasib
- Experimental
Phase 2 Cohort 1b: PD-L1 TPS <1%
Cohort 1b: Adagrasib BID monotherapy
Drug: Adagrasib
- Experimental
Phase 2 Cohort 2: PD-L1 TPS ≥1%
Cohort 2: Adagrasib BID in combination with pembrolizumab
Drug: Adagrasib
- Experimental
Phase 3 Cohort 3 Investigational Arm
Adagrasib BID in combination with pembrolizumab
Drug: Adagrasib
- Active comparator
Phase 3 Cohort 4 Comparator Arm
Pembrolizumab
Drug: Pembrolizumab
Interventions
AdagrasibDrug
Also known as Pembrolizumab
Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
AdagrasibDrug
Adagrasib 600 mg BID monotherapy (Cohort 1b)
AdagrasibDrug
Also known as Pembrolizumab
adagrasib 400 mg BID in combination with pembrolizumab
AdagrasibDrug
Also known as Pemrolizumab
Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
PembrolizumabDrug
Pembrolizumab 200 mg IV Q3W
What the study measures
Primary outcomes
Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
Objective Response Rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Time frame: 22 months
Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab
Progression Free Survival per RECIST 1.1 by Blinded Independent Central Review (BICR) and Overall Survival
Time frame: 36 months
Secondary outcomes
Phase 2: To characterize the safety and tolerability of study treatments in selected populations
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.
Time frame: 22 months
Phase 2: Duration of Response
Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.
Time frame: 22 months
Phase 2: Progression Free Survival
Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.
Time frame: 22 months
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
1-Year Survival rate
Time frame: 12 months
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
Overall Survival (OS)
Time frame: 22 months
Phase 2: To evaluate the pharmacokinetics (PK) of study treatments by measuring blood plasma MRTX849 and potential metabolite concentrations.
Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations
Time frame: 22 months
Phase 3: To evaluate the safety and tolerability in the study population
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.
Time frame: 36 months
Phase 3: To evaluate health-related quality of life (HRQOL) and lung cancer specific symptoms in the study population
Patient Reported Outcomes to measure quality of life
Time frame: 36 months
Phase 3: Progression Free Survival per RECIST 1.1 by Investigator
Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.
Time frame: 36 months
Phase 3: Duration of Response (DOR) per RECIST 1.1 by Investigator and BICR
Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.
Time frame: 36 months
Phase 3: Objective Response Rate (ORR) per RECIST 1.1 by Investigator and BICR
Defined as the percent of patients documented to have a confirmed CR or PR.
Time frame: 36 months
Who is running it
- Lead sponsor
- Mirati Therapeutics Inc.
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Mirati Therapeutics Inc.
- Data monitoring committee
- No
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- CA239-0009
- Other IDs
- CA239-0009, 849-007, 2023-508922-83, 2023
Bristol-Myers Squibb
Study director
Bristol-Myers Squibb
Study sites(770)
CIMS Hospital
Ahemdabad, India
Recruiting
- Bhavesh Parekh, Site 007-15689825034353
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre
Belagavi, India
Recruiting
- Rohan Bhise, Site 007-157509448866712
Marathwada Cancer Hospital & Research Institute
Chhatrapati Sambhajinagar, India
Recruiting
- Tushar Mule, Site 007-15659820493558
Basavatarakam Indo American Cancer Hospital & Research Institute
Hyderabad, India
Recruiting
Amrita Institute of Medical Sciences & Research Centre
Kochi, India
Recruiting
Netaji Subhas Chandra Bose Cancer Hospital
Kolkata, India
Recruiting
- Poulami Basu, Site 007-15706290073778
Meenakshi Mission Hospital and Research Centre
Madurai, India
Recruiting
- Saju SV, Site 007-15738891810070
Tata Memorial Centre - Tata Memorial Hospital
Mumbai, India
Recruiting
- Kumar Prabhash, Site 007-15829167760576
Mysore Medical College and Research Institute
Mysore, India
Recruiting
Indraprastha Apollo Hospitals
New Delhi, India
Recruiting
- Dipanjan Panda, Site 007-1567+919540946934
Indira Gandhi Institute of Medical Sciences
Patna, India
Recruiting
- Alok Ranjan, Site 007-1560+919572240838
Nirmal Hospital Pvt. Ltd.
Rajkot, India
Recruiting
Mahamana Pandit Madan Mohan Malviya Cancer Centre
Varanasi, India
Recruiting
- Anuj Gupta, Site 007-15819588229594
Local Institution - 007-1574
Ahmedabad, India
Not yet recruiting
Local Institution - 007-1586
Bangalore, India
Not yet recruiting
Local Institution - 007-1587
Howrah, India
Not yet recruiting
Local Institution - Shetty, R.
Mangalore, India
Not yet recruiting
Local Institution - 007-1588
New Delhi, India
Not yet recruiting
Local Institution - 007-1571
Pune, India
Not yet recruiting
Local Institution - 007-1564
Hyderabad, India
Withdrawn
Local Institution - 007-1569
Jaipur, India
Withdrawn
Local Institution - 007-1578
New Delhi, India
Withdrawn
USOR - Arizona Oncology - Prescott Valley
Prescott Valley, Arizona, United States
Recruiting
- Allan Espinosa Morazan, Site 007-556928-775-9430
Arizona Clinical Research Center
Tucson, Arizona, United States
Recruiting
- Manuel Modiano, Site 007-568520-290-2510
Highlands Oncology Group - Springdale
Springdale, Arkansas, United States
Recruiting
- Eric Schaefer, Site 007-978479-872-8130
Providence - Saint Joseph Home Health - Anaheim
Anaheim, California, United States
Recruiting
- Giribala Patel, Site 007-899714-446-5900
The Oncology Institute of Hope and Innovation - Corporate Office
Cerritos, California, United States
Recruiting
- Omkar Marathe, Site 007-898562-693-4477
MemorialCare - Long Beach Medical Center
Long Beach, California, United States
Recruiting
- Nilesh Vora, Site 007-936562-997-4070
TRIO - Cancer & Blood Specialty Clinic - Los Alamitos
Los Alamitos, California, United States
Recruiting
- Nihal Abdulla, Site 007-779562-706-6648
San Francisco Veterans Affairs Medical Center
San Francisco, California, United States
Recruiting
- Sunny Wang, Site 007-581415-221-4810x23380
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Recruiting
- Collin Blakely, Site 007-540415-502-6959
Providence Medical Group - Santa Rosa
Santa Rosa, California, United States
Recruiting
- Manasa Vulchi, Site 007-858707-521-3830
Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B)
Stockton, California, United States
Recruiting
- Sunny K. Philip, Jr., Site 007-582209-466-2626
USOR - Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado, United States
Recruiting
- Robert Jotte, Site 007-872303-430-2700
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States
Recruiting
- Dennis Slater, Site 007-949860-886-8362
GenesisCare USA
Aventura, Florida, United States
Recruiting
- Edgardo Santos, Site 007-552239-938-9315
Bay Pines Veterans Affairs Healthcare System
Bay Pines, Florida, United States
Recruiting
- Ryan Burri, Site 007-593727-398-6661
SCRI - Florida Cancer Specialists - South Region Research Office
Fort Myers, Florida, United States
Recruiting
- Fadi Kayali, Site 007-922239-274-9930
21st Century Oncology of Jacksonville - North Lee Street
Jacksonville, Florida, United States
Recruiting
- Troy Guthrie, Site 007-853904-805-7061
Cancer Specialists of North Florida - Southpoint
Jacksonville, Florida, United States
Recruiting
- Gaurav Trikha, Site 007-562203-530-1728
Showing 40 of 770 sites. 382 recruiting, 237 not recruiting and 151 cancelled; 22 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
- What is shared
- Study protocol, Sap, Csr
- When
- See Plan Description
- Access
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Source: ClinicalTrials.gov record NCT04613596, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.